» Articles » PMID: 34233729

Application of Mesenchymal Stem Cell Sheet to Treatment of Ischemic Heart Disease

Overview
Publisher Biomed Central
Date 2021 Jul 8
PMID 34233729
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, mesenchymal stem cells (MSCs) have been used to improve cardiac function and attenuate adverse ventricular remodeling of the ischemic myocardium through paracrine effects and immunoregulation functions. In combination with cell sheet technology, MSCs could be more easily transplanted to the ischemic area. The long-term retention of MSCs in the affected area was realized and significantly improved the curative effect. In this review, we summarized the research and the applications of MSC sheets to the treatment of ischemic heart tissue. At present, many types of MSCs have been considered as multipotent cells in the treatment of heart failure, such as bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose-derived mesenchymal stem cells (AD-MSCs), umbilical cord-derived mesenchymal stem cells (UC-MSCs), and skeletal myoblasts (SMs). Since UC-MSCs have few human leukocyte antigen-II and major histocompatibility complex class I molecules, and are easy to isolate and culture, UC-MSC sheets have been proposed as a candidate for clinical applications to ischemic heart disease.

Citing Articles

Preclinical Evaluation of the Safety, Toxicity and Efficacy of Genetically Modified Wharton's Jelly Mesenchymal Stem/Stromal Cells Expressing the Antimicrobial Peptide SE-33.

Gasanov V, Kashirskikh D, Khotina V, Kuzmina D, Nikitochkina S, Mukhina I Cells. 2025; 14(5).

PMID: 40072070 PMC: 11898551. DOI: 10.3390/cells14050341.


Umbilical cord-derived mesenchymal stromal cells: Promising therapy for heart failure.

Li Y, Chen E, Ren B World J Cardiol. 2025; 17(1):101153.

PMID: 39866217 PMC: 11755126. DOI: 10.4330/wjc.v17.i1.101153.


Current Advances and Future Directions of Pluripotent Stem Cells-Derived Engineered Heart Tissue for Treatment of Cardiovascular Diseases.

He X, Good A, Kalou W, Ahmad W, Dutta S, Chen S Cells. 2025; 13(24).

PMID: 39768189 PMC: 11674482. DOI: 10.3390/cells13242098.


Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with stem cell stemness and senescence.

Sun H, Zhai H, Han K, Ma H, Tan Y, Li S J Transl Med. 2024; 22(1):1039.

PMID: 39558365 PMC: 11575038. DOI: 10.1186/s12967-024-05814-3.


Control of myotube orientation using ultrasonication.

Hashiguchi R, Ichikawa H, Kumeta M, Koyama D Sci Rep. 2024; 14(1):25737.

PMID: 39468262 PMC: 11519932. DOI: 10.1038/s41598-024-77277-x.


References
1.
Yang L, Soonpaa M, Adler E, Roepke T, Kattman S, Kennedy M . Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008; 453(7194):524-8. DOI: 10.1038/nature06894. View

2.
Nakao M, Inanaga D, Nagase K, Kanazawa H . Characteristic differences of cell sheets composed of mesenchymal stem cells with different tissue origins. Regen Ther. 2019; 11:34-40. PMC: 6517796. DOI: 10.1016/j.reth.2019.01.002. View

3.
Ishida O, Hagino I, Nagaya N, Shimizu T, Okano T, Sawa Y . Adipose-derived stem cell sheet transplantation therapy in a porcine model of chronic heart failure. Transl Res. 2015; 165(5):631-9. DOI: 10.1016/j.trsl.2014.12.005. View

4.
Siltanen A, Kitabayashi K, Patila T, Ono M, Tikkanen I, Sawa Y . Bcl-2 improves myoblast sheet therapy in rat chronic heart failure. Tissue Eng Part A. 2010; 17(1-2):115-25. DOI: 10.1089/ten.TEA.2010.0205. View

5.
Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Ito E . Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation. 2013; 128(11 Suppl 1):S87-94. DOI: 10.1161/CIRCULATIONAHA.112.000366. View